Research programme: bispecific antibodies - Dana-Farber Cancer Institute/Harbour BioMed
Alternative Names: Anticancer therapeuticsLatest Information Update: 30 Jun 2021
At a glance
- Originator Dana-Farber Cancer Institute; Harbour BioMed
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 22 Jun 2021 Harbour BioMed has patent protection for Harbour Mice® platform (Harbor BioMed pipeline, June 2021)
- 16 Jun 2021 Harbour BioMed and Dana-Farber Cancer Institute agreed to co-develop Bispecific antibodies for the treatment of cancer
- 16 Jun 2021 Early research in Cancer in China (Parenteral) prior to June 2021